Severe elevation of blood pressure as high as 180/100; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/Blisters have opened leaving behind painful ulcers; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/Blisters have opened leaving behind painful ulcers; Painful ulcers; Painful ulcers; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/leaving behind painful ulcers; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/leaving behind painful ulcers; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/leaving behind painful ulcers; vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred/leaving behind painful ulcers; This is a spontaneous report from a contactable physician (patient/reported for himself). A 35-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL1283), via intramuscular on the left arm, on 21Jan2021 at 16:00 at single dose for covid-19 immunisation. The patient had no medical history. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and any other medications the patient received within 2 weeks of vaccination. The patient had no allergies to medications, food, or other products. No history of allergic reactions to any meds (medication) in the past or other vaccines in childhood. Otherwise young healthy male with no history of hypertension. The patient was not diagnosed with COVID-19 prior to vaccination. The patient concomitant medications were not reported. The patient previously took first dose of BNT162B2 (Lot number: EJ1686) via intramuscular on the left arm on 30Dec2020 at 16:00 for COVID-19 immunization and experienced severe elevation of blood pressure. On 22Jan2021, at 12:00 AM, after the 2nd dose in left arm, after about 24 to 48 hours, the patient experienced vesicular pruritic erythematous patches in multiple locations of my left arm, left arm pit, left upper back, left chest occurred, peaking on day three and still remain after one week. The blisters have opened leaving behind painful ulcers. This is not a rash that disappears in a few days. It will take much longer than that to heal. No rash with the first dose. Also, with both doses, had severe elevation of blood pressure as high as 180/100 within 2 to 5 hours on 22Jan2021, requiring about 3 doses of clonidine over 7 days where bp would cycle up and down. The seriousness of the events was reported as non-serious. Since the vaccination, the patient has been not tested for COVID-19. Therapeutic measures were taken as a result of events and included Benadryl, mometasone cream and clonidine. The outcome of the events was reported as recovering.  No follow-up attempts are needed. No further information is expected.; Sender's Comments: A causal association between BNT162B2 and the reported events cannot be excluded based on a compatible temporal relation. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.